EyePoint Nears Pivotal Data for Vision Drug Amid High-Stakes Spending

WATERTOWN, Mass. – May 06, 2026 – EyePoint, Inc. finds itself at a critical juncture, reporting widening financial losses while simultaneously heralding significant progress for its lead drug candidate, DURAVYU. In its first-quarter 2026 financial report released today, the biopharmaceutical company detailed a net loss of $84.8 million, nearly double the loss from the same period last year. The increased spending underscores a high-stakes strategy focused on bringing its potentially revolutionary treatment for serious retinal diseases to market, with pivotal clinical trial data expected in just a few months.

The company announced that its Phase 3 trials for DURAVYU in wet age-related macular degeneration (wet AMD) are on track for topline data beginning in mid-2026. This highly anticipated readout will be the first major test of a drug that EyePoint believes could become a 'best- and first-in-class' therapy, fundamentally altering the treatment landscape for millions of patients.

“We are entering an important time for EyePoint and the retina community,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, in the company's announcement. “DURAVYU is well positioned to potentially bring a new multi-mechanism of action sustained delivery treatment option to patients and physicians in these important retinal disease markets.”

A Potential Paradigm Shift in Retinal Care

Wet AMD and diabetic macular edema (DME) are leading causes of blindness, characterized by abnormal blood vessel growth and fluid leakage in the retina. The current standard of care involves frequent injections of anti-vascular endothelial growth factor (anti-VEGF) drugs like Eylea directly into the eye. While effective, this regimen imposes a significant “treatment burden” on patients, many of whom are elderly and require monthly or bimonthly visits to a specialist for the rest of their lives.

This relentless schedule often leads to patient anxiety, reliance on caregivers, and missed appointments, which can result in undertreatment and irreversible vision loss. DURAVYU aims to solve this problem directly. It is an intravitreal insert using EyePoint's proprietary Durasert E™ bioerodible technology to deliver a novel drug, vorolanib, for at least six months with a single administration. This could reduce a patient's injection schedule from up to 12 times a year to just two.

Beyond its sustained-delivery mechanism, DURAVYU's potential lies in its multi-pronged attack on the diseases. Vorolanib is a tyrosine kinase inhibitor that blocks not only VEGF receptors but also PDGF receptors, both key drivers of vessel leakage and growth. Furthermore, EyePoint presented new preclinical data at the recent Association for Research in Vision and Ophthalmology (ARVO) meeting, showing that vorolanib also potently inhibits IL-6 signaling, a key inflammatory pathway. This multi-mechanism action could offer a more comprehensive and robust effect than existing anti-VEGF monotherapies, particularly in complex conditions like DME where inflammation plays a major role.

Navigating a Crowded and Competitive Field

EyePoint is not alone in the race to reduce treatment burden. The retinal disease market, projected to surpass $27 billion by 2031, has attracted intense competition. Roche’s Susvimo, a refillable implant delivering ranibizumab, is already approved and offers a twice-yearly treatment. Meanwhile, Ocular Therapeutix's AXPAXLI, a hydrogel implant delivering a similar class of drug as DURAVYU, is also advancing through late-stage trials.

Further on the horizon are gene therapies from companies like Regenxbio, which aim to provide a one-time treatment by enabling the eye to produce its own therapeutic proteins. Against this backdrop, DURAVYU's success depends on demonstrating not only a significant reduction in treatment frequency but also a compelling efficacy and safety profile. Its unique triple-pathway inhibition could be a key differentiator, potentially offering benefits for patients who do not respond optimally to existing treatments.

The High Cost of Innovation

The company's Q1 2026 financial results paint a clear picture of the investment required to compete in this space. The reported net loss of $84.8 million, or $0.99 per share, was driven by a sharp increase in operating expenses to $87.9 million. The bulk of this, over $72 million, was dedicated to research and development, primarily for funding the four ongoing Phase 3 trials for DURAVYU and scaling up its commercial manufacturing facility.

Revenue for the quarter was a modest $0.7 million, a steep drop from the $24.5 million reported in Q1 2025. The company explained this was primarily due to the one-time recognition of deferred revenue from a past licensing agreement in the prior year, making the comparison misleading. The current financials reflect a company in a pre-commercial, all-in development phase.

Despite the high burn rate, EyePoint reported a cash and investment position of $223 million. Management stated this provides a financial runway into the fourth quarter of 2027, long enough to see the company past its most critical near-term milestones without needing to raise additional capital. This financial cushion is essential as the company awaits the data that will determine its fate.

All Eyes on Mid-2026 Data

The entire biopharma industry, along with investors and patients, will be watching closely this summer. The first data will come from the LUGANO trial, one of two identical Phase 3 studies for wet AMD that collectively enrolled over 900 patients. These trials are designed to prove DURAVYU is non-inferior to on-label aflibercept in terms of vision outcomes, with the key secondary goal of showing a vastly reduced treatment burden.

In parallel, the company’s Phase 3 trials for DME, named COMO and CAPRI, are rapidly enrolling patients, with over a third of the target population already signed on. Full enrollment is expected in the third quarter of this year, setting the stage for a topline data readout in late 2027. The promising safety profile observed across all previous trials has provided a foundation of confidence, but the upcoming efficacy data will be the ultimate arbiter of success. For EyePoint, the next few months represent the culmination of years of research and hundreds of millions of dollars in investment, with the potential to deliver a new standard of care for millions suffering from chronic, vision-threatening diseases.